EXAI BIO INC
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.3Mattributed |
|---|---|
| Latest round | grant, $1.3M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | palo alto, ca, usa |
| Industry | unknown |
| Stage | unknown |
| Website | exai.bio |
Exai Bio is developing an RNA-based liquid-biopsy platform that uses proprietary oncRNA biomarkers plus AI to detect early-stage cancer from a blood draw. Customers are clinicians and care pathways looking for non-invasive multi-cancer screening or recurrence monitoring. The team's pitch is finding cancer signals in what looks like noise to other platforms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $1.3M | undisclosed |
Detected tech stack
Cloudflare, Google Analytics, Google Font API, Google Hosted Libraries, Google Tag Manager, jsDelivr, WordPress, PHP, MySQL, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $1.3M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $1.3M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | exai.bio, read 2026-05-05 |
| Description | self-reported | exai.bio, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.